Physician profile
Brian Madow
NPI 1225187271
$2,835.09
in general payments reported to CMS, 2019-2025
12 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $1,123 · 2023: $799 · 2024: $501 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $781.62 | 2022-2024 | Yutiq, Iluvien |
| Regeneron Healthcare Solutions, INC. | $485.14 | 2021-2023 | Eylea, Eylea Hd |
| Genentech, INC. | $342.63 | 2022-2024 | Lucentis, Vabysmo, Susvimo |
| Genentech USA, INC. | $277.49 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $250.22 | 2022-2023 | Eylea |
| Apellis Pharmaceuticals, INC. | $199.91 | 2023-2024 | Syfovre |
| Eyepoint US, INC. | $163.47 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $124.99 | 2025 | Purified Cortrophin Gel |
| Alcon Vision LLC | $119.54 | 2021 | |
| Astellas Pharma US INC | $66.40 | 2024 | Izervay |
| Abbvie INC. | $23.68 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Madow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.